Pharming Group N.V. ADR (PHAR)

$12.97 -0.12 (-0.92%)
Market Cap 891.54M
Revenue (ttm) 376.13M
Net Income (ttm) 2.85M
EPS (ttm) N/A
PE Ratio 81.13
Forward PE 34.61
Profit Margin 0.76%
Debt to Equity Ratio 0.02
Volume 12,600
Avg Vol 17,946
Day's Range N/A - N/A
Shares Out 70.63M
Stochastic %K 24%
Beta 0.04
Analysts Strong Sell
Price Target $38.00

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 71 524 7400
Address:
Darwinweg 24, Leiden, Netherlands
nick2341
nick2341 May. 13 at 2:24 PM
$PHAR cashflow alright, making profit alright, and down all the way
0 · Reply
EmergingMarketDebt
EmergingMarketDebt May. 10 at 5:53 PM
$PHAR Pharmaceutical and healthcare-related company participating in treatment and drug-development markets
0 · Reply
Ruconestor
Ruconestor May. 10 at 2:54 PM
$PHAR De muisjes en nageboortes op IEX vullen hunvrije weekend weer met hun negatieve praatjes. Je kon voor weinig wat bijtanken donderdag maar ja , volgende week weer nieuwe kansen boys van t sterfhuis haha.
0 · Reply
MarketBeat
MarketBeat May. 8 at 8:03 PM
Pharming Group Q1 Earnings Call Highlights $PHAR #PharmingGroup #instantalerts #NASDAQ:PHAR https://www.marketbeat.com/instant-alerts/pharm
0 · Reply
Ruconestor
Ruconestor May. 7 at 3:05 PM
$PHAR Mooie koop nu , onzin daling
0 · Reply
HarrierduBois
HarrierduBois May. 7 at 2:14 PM
$PHAR
0 · Reply
Longterm007
Longterm007 May. 7 at 11:51 AM
$PHAR Dikke lul, wat een tegenvaller
0 · Reply
Ruconestor
Ruconestor Apr. 14 at 2:17 PM
$PHAR Ik zei het, het gaat los.
0 · Reply
Ruconestor
Ruconestor Apr. 13 at 1:31 PM
$PHAR Be there! Het gaat los.
1 · Reply
d_risk
d_risk Apr. 2 at 7:14 PM
$PHAR - Pharming Group N.V. ADS each representing 10 - 20F - Updated Risk Factors PHAR flags intensifying RUCONEST/Joenja competition from new 2025 prophylactic and acute HAE therapies (including oral and gene therapy candidates), rising global pricing/reimbursement pressure driven by MFN-style U.S. models and state cost controls, heightened trade/tariff and geopolitical risks to supply and sales, and new U.S. insider reporting rules, while prior ESG and internal-control material-weakness risks are dropped from the section. #Biopharmaceuticals #RareDiseaseTherapies #PricingPressure #GeopoliticalRisk #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/PHAR/20-F/2026-04-02
0 · Reply
Latest News on PHAR
Pharming price target lowered to $40 from $41 at Oppenheimer

2026-05-08T15:56:34.000Z - 5 days ago

Pharming price target lowered to $40 from $41 at Oppenheimer

Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026

2026-05-07T12:47:12.000Z - 6 days ago

Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026

Pharming Group Reports Lower Q1 Revenue, Highlights Joenja Growth And Regulatory Progress

2026-05-07T12:01:20.000Z - 6 days ago

Pharming Group Reports Lower Q1 Revenue, Highlights Joenja Growth And Regulatory Progress

Pharming Group Earnings Call Transcript: Q1 2026

May 7, 2026, 7:30 AM EDT - 6 days ago

Pharming Group Earnings Call Transcript: Q1 2026

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

May 7, 2026, 1:05 AM EDT - 6 days ago

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

PHAR

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

May 7, 2026, 1:00 AM EDT - 6 days ago

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

PHAR

Pharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of Earnings

2026-05-06T13:27:23.000Z - 7 days ago

Pharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of Earnings

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Apr 23, 2026, 2:00 AM EDT - 20 days ago

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

PHAR

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Apr 16, 2026, 2:00 AM EDT - 27 days ago

Pharming Group announces the 2026 Annual General Meeting of Shareholders

PHAR

Pharming Group Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 8:45 AM EDT - 4 weeks ago

Pharming Group Transcript: 25th Annual Needham Virtual Healthcare Conference

Pharming initiated with a Buy at Canaccord on growth potential

2026-04-10T11:00:17.000Z - 4 weeks ago

Pharming initiated with a Buy at Canaccord on growth potential

Pharming initiated with a Buy at Canaccord

2026-04-10T09:30:15.000Z - 4 weeks ago

Pharming initiated with a Buy at Canaccord

Pharming Group to participate in April investor conferences

Apr 7, 2026, 2:00 AM EDT - 5 weeks ago

Pharming Group to participate in April investor conferences

PHAR

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Apr 2, 2026, 1:00 AM EDT - 5 weeks ago

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

PHAR

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Mar 27, 2026, 2:00 AM EDT - 6 weeks ago

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

PHAR

Pharming announces approval of Joenja in Japan for patients aged 4 years and old

2026-03-24T15:06:07.000Z - 7 weeks ago

Pharming announces approval of Joenja in Japan for patients aged 4 years and old

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Mar 24, 2026, 2:00 AM EDT - 7 weeks ago

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

PHAR

Pharming price target lowered to $41 from $42 at Oppenheimer

2026-03-13T12:15:15.000Z - 2 months ago

Pharming price target lowered to $41 from $42 at Oppenheimer

Pharming Group Earnings Call Transcript: Q4 2025

Mar 12, 2026, 8:30 AM EDT - 2 months ago

Pharming Group Earnings Call Transcript: Q4 2025

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Mar 12, 2026, 2:00 AM EDT - 2 months ago

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

PHAR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Tue, 03 Mar 2026 14:14:00 -0500 - 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Thu, 26 Feb 2026 15:01:00 -0500 - 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

Feb 26, 2026, 2:00 AM EST - 2 months ago

Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

PHAR

Pharming Group Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 12:40 PM EST - 2 months ago

Pharming Group Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 2:00 AM EST - 3 months ago

Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

PHAR

Pharming Group Transcript: Investor Day 2026

Feb 3, 2026, 10:00 AM EST - 3 months ago

Pharming Group Transcript: Investor Day 2026

Pharming receives CRL from U.S. FDA for sNDA for Joenja

2026-02-01T23:45:07.000Z - 3 months ago

Pharming receives CRL from U.S. FDA for sNDA for Joenja

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

Feb 1, 2026, 3:17 PM EST - 3 months ago

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

PHAR

Pharming Group reports preliminary 2025 revenues and announces Investor Day

Jan 8, 2026, 1:00 AM EST - 4 months ago

Pharming Group reports preliminary 2025 revenues and announces Investor Day

PHAR

Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

Dec 8, 2025, 2:00 AM EST - 5 months ago

Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

PHAR

Pharming Group Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 5:00 AM EST - 6 months ago

Pharming Group Transcript: Jefferies London Healthcare Conference 2025

Pharming price target raised to $42 from $41 at Oppenheimer

2025-11-07T13:30:33.000Z - 6 months ago

Pharming price target raised to $42 from $41 at Oppenheimer

Pharming Group Earnings Call Transcript: Q3 2025

Nov 6, 2025, 7:30 AM EST - 6 months ago

Pharming Group Earnings Call Transcript: Q3 2025

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London

Oct 30, 2025, 3:00 AM EDT - 6 months ago

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London

PHAR

Pharming Group to report third quarter 2025 financial results and provide business update on November 6

Oct 23, 2025, 2:00 AM EDT - 7 months ago

Pharming Group to report third quarter 2025 financial results and provide business update on November 6

PHAR

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Oct 20, 2025, 2:00 AM EDT - 7 months ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

PHAR

Pharming announces 20% net reduction in non-commercial, non-medical headcount

2025-10-06T15:50:38.000Z - 7 months ago

Pharming announces 20% net reduction in non-commercial, non-medical headcount

Pharming Group provides update on previously announced G&A expense reduction plan

Oct 6, 2025, 11:35 AM EDT - 7 months ago

Pharming Group provides update on previously announced G&A expense reduction plan

PHAR

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Oct 1, 2025, 1:00 AM EDT - 8 months ago

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

PHAR

Pharming Group promoted to the Euronext AMX® index

Sep 10, 2025, 1:00 AM EDT - 8 months ago

Pharming Group promoted to the Euronext AMX® index

PHAR

Pharming Group Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 1:30 PM EDT - 8 months ago

Pharming Group Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 2:00 AM EDT - 9 months ago

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

PHAR

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Sep 2, 2025, 1:00 AM EDT - 9 months ago

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

PHAR

= Pharming Group NV ADS trading resumes

2025-08-08T16:10:55.000Z - 9 months ago

= Pharming Group NV ADS trading resumes

PHAR

= Pharming Group NV ADS trading halted, volatility trading pause

2025-08-08T15:45:34.000Z - 9 months ago

= Pharming Group NV ADS trading halted, volatility trading pause

PHAR

Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital

2025-08-06T16:55:33.000Z - 10 months ago

Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital

Pharming Group to participate in August investor conference

Aug 4, 2025, 2:00 AM EDT - 10 months ago

Pharming Group to participate in August investor conference

PHAR

Pharming price target raised to $41 from $40 at Oppenheimer

2025-08-01T12:10:29.000Z - 10 months ago

Pharming price target raised to $41 from $40 at Oppenheimer

Pharming Group Earnings Call Transcript: Q2 2025

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Pharming Group Earnings Call Transcript: Q2 2025

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Jul 31, 2025, 1:00 AM EDT - 10 months ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

PHAR

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Jul 17, 2025, 2:00 AM EDT - 10 months ago

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

PHAR

Pharming Group Transcript: Study Update

Jun 30, 2025, 10:30 AM EDT - 11 months ago

Pharming Group Transcript: Study Update

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 24, 2025, 1:00 AM EDT - 11 months ago

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

PHAR

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Jun 11, 2025, 11:15 AM EDT - 1 year ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

PHAR

Pharming Group Transcript: AGM 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Pharming Group Transcript: AGM 2025

Pharming Group Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 2:00 PM EDT - 1 year ago

Pharming Group Transcript: Jefferies Global Healthcare Conference 2025

Pharming Group to participate in June investor conferences

May 28, 2025, 2:00 AM EDT - 1 year ago

Pharming Group to participate in June investor conferences

PHAR

Pharming Group Earnings Call Transcript: Q1 2025

May 8, 2025, 7:30 AM EDT - 1 year ago

Pharming Group Earnings Call Transcript: Q1 2025

Pharming Group reports first quarter 2025 financial results and provides business update

May 8, 2025, 1:00 AM EDT - 1 year ago

Pharming Group reports first quarter 2025 financial results and provides business update

PHAR

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 30, 2025, 11:45 AM EDT - 1 year ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

PHAR

Pharming Group to report first quarter 2025 financial results on May 8

Apr 24, 2025, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2025 financial results on May 8

PHAR

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 23, 2025, 3:30 AM EDT - 1 year ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

PHAR

Pharming Group Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Pharming Group Transcript: 24th Annual Needham Virtual Healthcare Conference

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Apr 3, 2025, 1:00 AM EDT - 1 year ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

PHAR

Pharming Group Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Pharming Group Earnings Call Transcript: Q4 2024

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 13, 2025, 2:00 AM EDT - 1 year ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

PHAR

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Mar 4, 2025, 9:15 AM EST - 1 year ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

PHAR

Pharming Group Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 8:40 AM EST - 1 year ago

Pharming Group Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Feb 7, 2025, 4:00 PM EST - 1 year ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

PHAR

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 12:00 PM EST - 1 year ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

PHAR

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Jan 21, 2025, 1:00 AM EST - 1 year ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

PHAR

Pharming Group Transcript: M&A Announcement

Dec 16, 2024, 8:00 AM EST - 1 year ago

Pharming Group Transcript: M&A Announcement

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 15, 2024, 1:45 PM EST - 1 year ago

Pharming announces public cash offer to the shareholders of Abliva AB

PHAR

Pharming Group Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

Pharming Group Transcript: Jefferies London Healthcare Conference 2024

Pharming Group to participate in November investor conference

Nov 5, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in November investor conference

PHAR

Pharming Group Earnings Call Transcript: Q3 2024

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Pharming Group Earnings Call Transcript: Q3 2024

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report third quarter 2024 financial results on October 24

PHAR

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Oct 10, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

PHAR

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 26, 2024, 1:00 AM EDT - 1 year ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

PHAR

Pharming Group Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 10:30 AM EDT - 1 year ago

Pharming Group Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Pharming Group Transcript: Wells Fargo 2024 Healthcare Conference

Sep 6, 2024, 8:45 AM EDT - 1 year ago

Pharming Group Transcript: Wells Fargo 2024 Healthcare Conference

Pharming Group to participate in September investor conferences

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group to participate in September investor conferences

PHAR

Pharming Group Earnings Call Transcript: H1 2024

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Pharming Group Earnings Call Transcript: H1 2024

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

PHAR

Pharming Group to report second quarter and first half 2024 financial results on August 1

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

PHAR

Pharming Group Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 10:30 AM EDT - 2 years ago

Pharming Group Transcript: Jefferies 2024 Global Healthcare Conference

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 30, 2024, 4:44 PM EDT - 2 years ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

PHAR

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 21, 2024, 11:30 AM EDT - 2 years ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

PHAR

nick2341
nick2341 May. 13 at 2:24 PM
$PHAR cashflow alright, making profit alright, and down all the way
0 · Reply
EmergingMarketDebt
EmergingMarketDebt May. 10 at 5:53 PM
$PHAR Pharmaceutical and healthcare-related company participating in treatment and drug-development markets
0 · Reply
Ruconestor
Ruconestor May. 10 at 2:54 PM
$PHAR De muisjes en nageboortes op IEX vullen hunvrije weekend weer met hun negatieve praatjes. Je kon voor weinig wat bijtanken donderdag maar ja , volgende week weer nieuwe kansen boys van t sterfhuis haha.
0 · Reply
MarketBeat
MarketBeat May. 8 at 8:03 PM
Pharming Group Q1 Earnings Call Highlights $PHAR #PharmingGroup #instantalerts #NASDAQ:PHAR https://www.marketbeat.com/instant-alerts/pharm
0 · Reply
Ruconestor
Ruconestor May. 7 at 3:05 PM
$PHAR Mooie koop nu , onzin daling
0 · Reply
HarrierduBois
HarrierduBois May. 7 at 2:14 PM
$PHAR
0 · Reply
Longterm007
Longterm007 May. 7 at 11:51 AM
$PHAR Dikke lul, wat een tegenvaller
0 · Reply
Ruconestor
Ruconestor Apr. 14 at 2:17 PM
$PHAR Ik zei het, het gaat los.
0 · Reply
Ruconestor
Ruconestor Apr. 13 at 1:31 PM
$PHAR Be there! Het gaat los.
1 · Reply
d_risk
d_risk Apr. 2 at 7:14 PM
$PHAR - Pharming Group N.V. ADS each representing 10 - 20F - Updated Risk Factors PHAR flags intensifying RUCONEST/Joenja competition from new 2025 prophylactic and acute HAE therapies (including oral and gene therapy candidates), rising global pricing/reimbursement pressure driven by MFN-style U.S. models and state cost controls, heightened trade/tariff and geopolitical risks to supply and sales, and new U.S. insider reporting rules, while prior ESG and internal-control material-weakness risks are dropped from the section. #Biopharmaceuticals #RareDiseaseTherapies #PricingPressure #GeopoliticalRisk #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/PHAR/20-F/2026-04-02
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 24 at 2:21 PM
$PHAR
0 · Reply
nick2341
nick2341 Mar. 24 at 6:16 AM
$PHAR japan
2 · Reply
nick2341
nick2341 Mar. 24 at 6:14 AM
$PHAR approved!
0 · Reply
BGG13
BGG13 Mar. 23 at 3:55 PM
$PHAR EMA CHMP agenda: 3.1.4. Leniolisib - Orphan - EMEA/H/C/005927 Pharming Technologies B.V.; treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) Scope: Opinion Action: For adoption List of Outstanding Issues adopted on 30.05.2024, 25.01.2024, 09.11.2023, 20.07.2023. List of Questions adopted on 24.01.2023.
0 · Reply
ZacksResearch
ZacksResearch Mar. 3 at 1:41 PM
$PHAR heading into Q4 — make-or-break moment? 👀 All eyes are on Ruconest and Joenja sales as Pharming Group gears up to report, with pipeline updates and clarity around key regulatory setbacks front and center. This isn’t just another quarter — it’s about confidence going forward. Will management steady the ship or raise new questions? Full breakdown before earnings 👉 https://www.zacks.com/stock/news/2877894/pharming-group-gears-up-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2877894-teaser-35821&ADID=SYND_STOCKTWITS_TWEET_2_2877894_TEASER_35821
0 · Reply
ZacksResearch
ZacksResearch Mar. 3 at 12:41 PM
$PHAR's Q4 earnings: Can Ruconest drive growth amidst challenges? 🤔 💊 Focus on Ruconest sales, expected to have boosted Q4 figures, despite the withdrawal from non-U.S. markets 🌍 Joenja sales expected to grow, driven by an increase in U.S. and U.K. patients on paid therapy 🔍 Investors await updates on pipeline setbacks and regulatory hurdles Full analysis here 👉 https://www.zacks.com/stock/news/2877894/pharming-group-gears-up-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2877894-body-35822&ADID=SYND_STOCKTWITS_TWEET_2_2877894_BODY_35822
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 8:02 PM
$PHAR RSI: 44.86, MACD: -0.4008 Vol: 0.52, MA20: 16.35, MA50: 17.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 11:09 AM
$PHAR Current Stock Price: $16.36
0 · Reply
EmotionlessMarket
EmotionlessMarket Feb. 18 at 3:29 PM
$PHAR Pharming Group operates a niche rare-disease portfolio with recurring revenue but limited growth. Pipeline execution is required to change valuation dynamics. Cash flow stability provides downside support.
2 · Reply
BillionerOfKing
BillionerOfKing Feb. 13 at 5:15 PM
$PHAR Current Stock Price: $15.74
0 · Reply
nick2341
nick2341 Feb. 9 at 12:04 PM
$PHAR Good morning 🌅
0 · Reply
MacroSculptor
MacroSculptor Feb. 4 at 2:22 PM
$PHAR is a clinical-stage biotech developing therapies for cancer and inflammatory diseases; its pipeline is in early development, representing a high-risk investment.
1 · Reply